RESUMO
N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine 12 (GSK962040) is a novel small molecule motilin receptor agonist. It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist activity results in potentiation of the amplitude of neuronal-mediated contractions of isolated gastric antrum tissue. Compound 12 also possesses highly promising pharmacokinetic profiles in both rat and dog, and these results, in combination with further profiling in human native tissue and an in vivo model of gastrointestinal transit in the rabbit, have led to its selection as a candidate for further development.
Assuntos
Descoberta de Drogas , Fármacos Gastrointestinais/farmacologia , Piperazinas/farmacologia , Piperidinas/farmacologia , Antro Pilórico/efeitos dos fármacos , Receptores dos Hormônios Gastrointestinais/agonistas , Receptores de Neuropeptídeos/agonistas , Animais , Cães , Motilidade Gastrointestinal/efeitos dos fármacos , Humanos , Contração Muscular/efeitos dos fármacos , Piperazinas/química , Piperidinas/química , Antro Pilórico/fisiologia , Coelhos , RatosRESUMO
We describe the generation of novel EP(1) receptor antagonists by investigation of thiophene isosteres. In addition, we disclose preliminary in vitro and in vivo DMPK for selected compounds.